What will you answer when a potential investor asks you how and when they’ll get a return on their investment?
Whatever your company’s ambitions are in terms of Initial Public Offering (IPO), Mergers & Acquisitions (M&A) or licensure, you will probably want to keep your options open in the early stages of your company’s development. Have you identified your long-term exit strategy, including your strategic endgame and a plan for getting there?
During this interactive session Johnson & Johnson Innovation aims to provide a no-nonsense guide to key aspects of exits through M&A, focused on early-stage life sciences and medtech companies with deep IP.
The programme will be led by experts from Allen & Overy’s market-leading technology team who have deep experience in Mergers & Acquisitions (M&A) in different global ecosystems including Silicon Valley. They will share insights into:
- what to expect from acquirers and investors;
- how to create a strong position for negotiations;
- approaches you might expect from buyers;
- differences between the USA, UK and EU;
- common pitfalls and how to avoid them.
Agenda
10:30 CEST Registration open for in-person attendees
11:00 CEST Introduction by Johnson & Johnson Innovation
Niels Wheeler | Innovation Activation Manager, Johnson & Johnson Innovation
11:10 CEST Workshop by Allen & Overy
Will Samengo-Turner | Partner, Allen & Overy
Eimear Coady | Senior Associate, Allen & Overy
12:30 CEST Lunch break (basic lunch will be provided for in-person attendees)
13:30 CEST One-to-one mentoring meetings with selected companies
17:00 CEST Event Close
Following the workshop, Allen & Overy will provide one-to-one mentoring sessions (25 minutes each) for selected companies. Please see here for more information including application details.
More information about the speakers can be found on the website. Registration is possible here.
Source: Johnson & Johnson